Karen Swisher, MD
Medical Oncology · Salina, KSNPI 1528176955
Payments from drug & device makers
Across 110 payments — averaging $71.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Sanofi$2K
- US Oncology Corporate, Inc.$2K
- Novartis$211
- Bristol Myers Squibb$164
- Pfizer$102
- plus $1K from 32 others
What the payments were for
- Consulting fees$3,79848%
- Travel & lodging$1,02213%
- Food & beverage$3,06439%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 15 | $2,594 |
| Sanofi | 2 | $1,894 |
| US Oncology Corporate, Inc. | 5 | $1,675 |
| Novartis | 11 | $211 |
| Bristol Myers Squibb | 8 | $164 |
| Pfizer | 6 | $102 |
| Incyte Corporation | 6 | $100 |
| Johnson & Johnson | 4 | $97 |
| Gilead | 4 | $82 |
| Merck | 4 | $81 |
| Exelixis Inc. | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| AVEO Pharmaceuticals, Inc. | 2 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $60 |
| Genentech USA, Inc. | 3 | $59 |
| AbbVie | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Eisai Inc. | 2 | $43 |
| Seagen Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Acrotech Biopharma Inc. | 1 | $32 |
| Sobi, Inc | 1 | $27 |
| Lilly USA, LLC | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $26 |
| Boston Scientific | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $21 |
| Array Biopharma Inc | 1 | $21 |
| Geron Corporation | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| CTI Biopharma Corp. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Bayer | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Vapotherm Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,905 in reported general payments places this provider in the 25th percentile of 25 medical oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 19 | $263,440 |
| CalquenceAcalabrutinib Maleate | 13 | $200,698 |
| IbrancePalbociclib | 11 | $172,290 |
| EliquisApixaban | 39 | $22,863 |
| Acyclovir | 98 | $1,340 |
| Hydroxyurea | 37 | $762 |
| Anastrozole | 68 | $686 |
| Exemestane | 12 | $645 |
| Tamoxifen Citrate | 30 | $553 |
| Anagrelide Hcl | 14 | $510 |
| Pregabalin | 12 | $443 |
| Megestrol Acetate | 11 | $437 |
| Allopurinol | 35 | $421 |
| Ondansetron OdtOndansetron | 33 | $371 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 77 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $2,594 | $200,69813 claims |
| PfizerIbrance, Eliquis | $102 | $195,15350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 25 medical oncology providers in Kansas.
Other medical oncology in Salina
- Weijing SunWestwood$5.1M
- Rahul ParikhWestwood$4.5M
- Anwaar SaeedWestwood$4.1M
- Ajjai AlvaOverland Park$3.7M
- Joaquina BarandaWestwood$2.7M
- Anne OdeaWestwood$2.2M
- Nisreen HaideriOverland Park$1.2M
- Benjamin GeorgeColby$1.1M
- Stephen WilliamsonWestwood$861K
- Elizabeth WulffWestwood$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.